Skip to main content
Top
Published in: International Journal of Hematology 4/2009

01-11-2009 | Case Report

Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia

Authors: Shiho Fujiwara, Hirosada Miyake, Kisato Nosaka, Minoru Yoshida, Sonoko Ishihara, Kentaro Horikawa, Yuji Yonemura, Kenichi Iyama, Hiroaki Mitsuya, Norio Asou

Published in: International Journal of Hematology | Issue 4/2009

Login to get access

Abstract

Hairy cell leukemia (HCL) is occasionally misdiagnosed as aplastic anemia when only a few leukemic cells are present in the circulation. Here, we describe a patient with HCL who initially presented with pancytopenia and received a diagnosis of aplastic anemia. The patient was treated with immunosuppressive therapy including cyclosporine A and anti-thymocyte globulin (ATG). No blood cell transfusion was required for approximately 3 years after ATG therapy. She was referred to our hospital because of an abdominal mass and requiring periodic blood transfusions. A bone marrow biopsy at this time revealed proliferation of lymphocytes with a fried egg appearance and an increase in reticulin fibers that are typical findings of HCL. It is notable that our patient with a presumably long history of HCL and an increase in marrow reticulin fibers showed good recovery of hematopoiesis after cladribine therapy. Some HCL patients may receive an initial diagnosis of aplastic anemia and may show a good response to ATG masking the underlying HCL.
Literature
1.
go back to reference Allsup DJ, Cawley JC. The diagnosis and treatment of hairy-cell leukaemia. Blood Rev. 2002;16:255–62.CrossRefPubMed Allsup DJ, Cawley JC. The diagnosis and treatment of hairy-cell leukaemia. Blood Rev. 2002;16:255–62.CrossRefPubMed
2.
go back to reference Wanko SO, de Castro C. Hairy cell leukemia: an elusive but treatable disease. Oncologist. 2006;11:780–9.CrossRefPubMed Wanko SO, de Castro C. Hairy cell leukemia: an elusive but treatable disease. Oncologist. 2006;11:780–9.CrossRefPubMed
3.
go back to reference Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer. 2006;6:437–48.CrossRefPubMed Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer. 2006;6:437–48.CrossRefPubMed
4.
go back to reference Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43:185–90.CrossRefPubMed Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43:185–90.CrossRefPubMed
5.
go back to reference Krause JR. Aplastic anemia terminating in hairy cell leukemia: a report of two cases. Cancer. 1984;53:1533–7.CrossRefPubMed Krause JR. Aplastic anemia terminating in hairy cell leukemia: a report of two cases. Cancer. 1984;53:1533–7.CrossRefPubMed
7.
go back to reference Sugimori C, Kaito K, Nakao S. Persistent remission after immunosuppressive therapy of hairy cell leukemia mimicking aplastic anemia: two case reports. Int J Hematol. 2003;77:391–4.CrossRefPubMed Sugimori C, Kaito K, Nakao S. Persistent remission after immunosuppressive therapy of hairy cell leukemia mimicking aplastic anemia: two case reports. Int J Hematol. 2003;77:391–4.CrossRefPubMed
8.
go back to reference Humphries JE. Dry tap bone marrow aspiration: clinical significance. Am J Hematol. 1990;35:247–50.CrossRefPubMed Humphries JE. Dry tap bone marrow aspiration: clinical significance. Am J Hematol. 1990;35:247–50.CrossRefPubMed
9.
go back to reference Tsuge I, Kojima S. Comparison of antibody specificities of four anti-thymocyte/anti-lymphocyte globulin products. Curr Ther Res. 1995;56:671–7.CrossRef Tsuge I, Kojima S. Comparison of antibody specificities of four anti-thymocyte/anti-lymphocyte globulin products. Curr Ther Res. 1995;56:671–7.CrossRef
10.
go back to reference Bonnefoy-Berard N, Verrier B, Vincent C, Revillard JP. Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins. Immunology. 1992;77:61–7.PubMedPubMedCentral Bonnefoy-Berard N, Verrier B, Vincent C, Revillard JP. Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins. Immunology. 1992;77:61–7.PubMedPubMedCentral
11.
go back to reference Chilosi M, Semenzato G, Cetto G, Ambrosetti A, Fiore-Donati L, Perona G, et al. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood. 1987;70:1530–5.PubMed Chilosi M, Semenzato G, Cetto G, Ambrosetti A, Fiore-Donati L, Perona G, et al. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood. 1987;70:1530–5.PubMed
12.
go back to reference Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL, et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood. 1988;71:1304–9.PubMed Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL, et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood. 1988;71:1304–9.PubMed
Metadata
Title
Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia
Authors
Shiho Fujiwara
Hirosada Miyake
Kisato Nosaka
Minoru Yoshida
Sonoko Ishihara
Kentaro Horikawa
Yuji Yonemura
Kenichi Iyama
Hiroaki Mitsuya
Norio Asou
Publication date
01-11-2009
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0427-x

Other articles of this Issue 4/2009

International Journal of Hematology 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine